Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement

Advances in Radiation Oncology · Published 2026-06-01 · DOI 10.1016/j.adro.2026.102101

Free full text

Authors (7)

Peter Orio, Grgur Mirić, Robert Galbreath, Shalini Moningi, Ryan Fiano, Kent Wallner, Martin King

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Orio, P., Mirić, G., Galbreath, R., et al. (2026). Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement. Advances in Radiation Oncology. https://doi.org/10.1016/j.adro.2026.102101

Related articles